EVFM has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
EVFM has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Evofem Biosciences's shares outstanding for the quarter that ended in Mar. 2024 was 48.71 Mil.
Evofem Biosciences's quarterly shares outstanding increased from Dec. 2023 (20.01 Mil) to Mar. 2024 (48.71 Mil). It means Evofem Biosciences issued new shares from Dec. 2023 to Mar. 2024 .
Evofem Biosciences's annual shares outstanding increased from Dec. 2022 (0.98 Mil) to Dec. 2023 (20.01 Mil). It means Evofem Biosciences issued new shares from Dec. 2022 to Dec. 2023 .
The historical data trend for Evofem Biosciences's Shares Outstanding (EOP) can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Evofem Biosciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 0.03 | 0.04 | 0.09 | 0.98 | 20.01 |
Evofem Biosciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
Shares Outstanding (EOP) | Get a 7-Day Free Trial | 1.73 | 2.52 | 5.68 | 20.01 | 48.71 |
For the Biotechnology subindustry, Evofem Biosciences's Shares Outstanding (EOP), along with its competitors' market caps and Shares Outstanding (EOP) data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Evofem Biosciences's Shares Outstanding (EOP) distribution charts can be found below:
* The bar in red indicates where Evofem Biosciences's Shares Outstanding (EOP) falls into.
Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.
Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.
Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that end of period. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.
Evofem Biosciences (OTCPK:EVFM) Shares Outstanding (EOP) Explanation
A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.
Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.
Be Aware
Warren Buffett looks for consistency and upward long term trend. Because of share repurchase it is possible for net earnings trend to differ from EPS trend. He preferred net income over EPS. The companies with durable competitive advantage companies report higher % net earnings to total revenues.
Important: If a company is showing net earnings history greater than 20% on total revenues, it is probably benefiting from a long term competitive advantage.
If net earnings is less than 10%, likely to be in a highly competitive business.
Thank you for viewing the detailed overview of Evofem Biosciences's Shares Outstanding (EOP) provided by GuruFocus.com. Please click on the following links to see related term pages.
Yan Zhang | officer: Chief Financial Officer | 6166 TIKI CT, SAN DIEGO CA 92130 |
Kim P. Kamdar | director, 10 percent owner | C/O DOMAIN ASSOCIATES, L.L.C., ONE PALMER SQUARE, SUITE 515, PRINCETON NJ 08542 |
Jenny C. Yip | director | 12400 HIGH BLUFF DR., STE. 600, SAN DIEGO CA 92130 |
Atkinson Katherine Cocca | officer: Chief Commercial Officer | 12400 HIGH BLUFF., STE. 600, SAN DIEGO CA 92130 |
Saundra L Pelletier | director, officer: Chief Executive Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Alexander A Fitzpatrick | officer: General Counsel and Secretary | 9605 SCRANTON ROAD, SUITE 200, SAN DIEGO CA 92121 |
Justin J. File | officer: Chief Financial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Anthony Stephen O'brien | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Russell Barrans | officer: Chief Commercial Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
Lisa Dale Rarick | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, STE 600, SAN DIEGO CA 92130 |
William Walmsley Hall | director | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DIRVE, SUITE 600, SAN DIEGO CA 92130 |
Invesco Ltd. | 10 percent owner | 1331 SPRING STREET NW, SUITE 2500, ATLANTA GA 30309 |
Link Fund Solutions Ltd | 10 percent owner | 65 GRESHAM STREET, LONDON X0 EC2V 7NQ |
Acacia Research Corp | 10 percent owner | 767 3RD AVENUE, 6TH FLOOR, NEW YORK NY 10017 |
Kelly Culwell | officer: Chief Medical Officer | C/O EVOFEM BIOSCIENCES, INC., 12400 HIGH BLUFF DRIVE, SUITE 600, SAN DIEGO CA 92130 |
From GuruFocus
By PRNewswire • 10-13-2023
By PRNewswire • 12-12-2023
By PRNewswire PRNewswire • 01-12-2023
By PRNewswire • 11-14-2023
By PRNewswire • 10-24-2023
By PRNewswire • 07-06-2023
By PRNewswire PRNewswire • 08-01-2022
By PRNewswire PRNewswire • 02-23-2023
By PRNewswire • 09-27-2023
By PRNewswire • 09-11-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.